CLDI — Calidi Biotherapeutics Balance Sheet
0.000.00%
- $11.30m
- $18.04m
Annual balance sheet for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Short Term Investments | 0.42 | 2.14 | 0.372 | 1.95 |
Prepaid Expenses | ||||
Total Current Assets | 0.513 | 2.74 | 0.786 | 4.3 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0.723 | 0.585 | 1.09 | 5.34 |
Long Term Investments | ||||
Other Long Term Assets | ||||
Total Assets | 1.85 | 3.39 | 2.6 | 10 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 8.89 | 26 | 43 | 10.2 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 15.3 | 26 | 43.4 | 18.3 |
Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | -13.5 | -22.6 | -40.8 | -8.23 |
Total Liabilities & Shareholders' Equity | 1.85 | 3.39 | 2.6 | 10 |
Total Common Shares Outstanding |